42 
Monitoring Stem Cell Research 
The NIH now believes the actual number to be somewhat 
higher, so that seventy-eight lines (or preparations) are known 
to be eligible for funding.* The lines are held by universities, 
companies, and other entities throughout the world. According 
to the National Institutes of Health’s latest report (September 
2003), the following organizations have developed stem cell 
derivations eligible for federal funding (that is, derived prior to 
August 9, 2001, under the approved conditions): 
Number of 
Name Derivations 
BresaGen, Inc., Athens, Georgia 4 
CyThera, Inc., San Diego, California 9 
ES Cell International, Melbourne, Australia 6 
Geron Corporation, Menlo Park, California 7 
Goteborg University, Goteborg, Sweden 19 
Karolinska Institute, Stockholm, Sweden 6 
Maria Biotech Co. Ltd. - Maria Infertility 
Hospital Medical Institute, Seoul, Korea 
MizMedi Hospital - Seoul National Univer- 
sity, Seoul, Korea 
National Centre for Biological Sciences/ 
Tata Institute of Fundamental Research, 3 
Bangalore, India 
Pochon CHA University, Seoul, Korea 2 
Reliance Life Sciences, Mumbai, India 7 
Technion University, Haifa, Israel 4 
University of California, San Francisco, ^ 
California 
Wisconsin Alumni Research Foundation, ^ 
Madison, Wisconsin 
Although all of these lines (or preparations) are deemed eli- 
gible for funding according to the criteria of the administra- 
tion’s policy, not all are presently available for use by re- 
* These numbers took almost everyone by surprise. Prior to the President’s 
announcement, the best estimates of the number of human embryonic stem 
cell lines then existing worldwide ranged between 10 and 20. But eligibility 
is not the same thing as availability, as we will discuss. 
PRE-PUBLICATION VERSION 
